Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.
about
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6BCholine Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New AntimicrobialsMaternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspringImmunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.Interaction of pneumococcal histidine triad proteins with human complement.Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniaeA bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice.Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.Next generation pneumococcal vaccinesMucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholineControlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.Modulation of bacterial pathogenesis by oppressive aging factors: insights into host-pneumococcal interaction strategiesModified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein AAnatomical site-specific contributions of pneumococcal virulence determinants.Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infantsA modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).Cord blood Streptococcus pneumoniae-specific cellular immune responses predict early pneumococcal carriage in high-risk infants in Papua New Guinea.Current status and perspectives on protein-based pneumococcal vaccines.Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice.Phenotypic and molecular characterization of optochin-resistant Streptococcus pneumoniae isolates from Brazil, with description of five novel mutations in the ATPC gene.Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences.
P2860
Q24644461-BD7F5570-D385-4E8E-91BF-5F3780610737Q26744448-0283ECE0-2A19-4384-A988-4C6C4EF09939Q28743311-4C010823-F414-4451-907A-82DED6DF864CQ33725192-33CA3C47-5F60-4BF6-AA8B-5A53D92D4947Q33826119-58DC97FA-95D6-41E8-9E31-B31882A21351Q34309712-1985F22B-D7AC-4255-BE19-20B6DE320867Q34594671-99DD3668-C518-45EF-8E71-DC148909F08FQ34664119-BECC9058-81D7-420D-98F8-01FEF693D04DQ34784957-DAFBE2BE-E5AE-48F3-8A76-38E9BDF7236BQ35028495-951D5D10-3565-47A3-A760-6C6B83D64752Q35805480-449A3CC3-7A97-4729-A573-25E96E0538E1Q36015321-92E5F419-0248-4A0A-BAF9-898CDC46092FQ36306944-8254DF62-B844-4A59-8B96-3716EB5572FBQ36362263-0E04B7FF-4380-4033-BF0F-EB53678FD4B6Q36454995-D9FA6E10-CB43-4143-BF75-71105B470A04Q36999810-65D234BF-2C2A-4450-94D1-B00EB115FA76Q37152982-C0E40B65-4A5A-45C6-A26A-1833AB2F7C41Q37252358-5AB8C263-6D7B-46F6-A66D-658286CF2BC5Q37252799-7676BA2B-AA61-41F3-B23A-558199CFCB3BQ37410062-F83798F9-5C51-43B2-9DA7-8219C9ED458FQ37483596-6A595BA7-821A-4DF0-AE32-4CBB96618E67Q37622565-5EBD9D8F-10CD-4251-863E-6660484CD806Q38124921-50F5493F-F442-452E-8958-E28A318583AEQ39164566-EE753668-CFC4-46C7-8CD5-23C3E6B2B89CQ40277871-62030CF6-08A1-41CC-84EA-A669D687C434Q41821802-910E0597-E6EB-484F-BD08-290E66942516Q47405455-540DEF35-9B7D-4797-976D-7FD96C4A62EBQ54349086-CE291E8B-5B18-43B3-AEB2-91887E419DE5
P2860
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@en
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@nl
type
label
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@en
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@nl
prefLabel
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@en
Vaccine-induced human antibodi ...... n on Streptococcus pneumoniae.
@nl
P2093
P2860
P1476
Vaccine-induced human antibodi ...... on on Streptococcus pneumoniae
@en
P2093
Audra Jurkuvenas
Bryony Hicks
David E Briles
Martina M Ochs
William Bartlett
P2860
P304
P356
10.1016/J.MICPATH.2007.09.007
P577
2007-10-11T00:00:00Z